respiratori
syncyti
viru
rsv
ubiquit
respiratori
viru
afflict
peopl
although
wide
recogn
lead
caus
lower
respiratori
tract
infect
young
children
rsv
also
caus
signific
adult
chronic
obstruct
pulmonari
diseas
copd
congest
heart
failur
chf
affect
million
peopl
worldwid
identifi
risk
factor
sever
rsv
addit
patient
may
present
primarili
symptom
decompens
heart
failur
acut
exacerb
copd
aecopd
role
viral
infect
although
molecular
diagnost
test
markedli
improv
recognit
rsv
respiratori
virus
set
adult
rsv
remain
underrecogn
problem
effect
mean
prevent
infecti
diseas
vaccin
approach
deploy
protect
largest
group
possibl
present
success
rsv
vaccin
remain
elus
passiv
immunoprophylaxi
monoclon
antibodi
palivizumab
infant
shown
reduc
rsv
although
older
adult
increas
risk
sever
rsv
infect
certain
subgroup
sever
copd
chf
may
even
greater
risk
could
potenti
benefit
passiv
immunoprophylaxi
infect
rate
sever
found
substanti
limit
data
avail
incid
rsv
infect
adult
class
iii
iv
copd
andor
chf
observ
studi
design
collect
data
popul
adult
exposur
children
might
exhibit
high
rate
infect
sever
ill
infect
rsv
prospect
observ
studi
conduct
across
multipl
consecut
rsv
season
determin
incid
rate
medic
attend
acut
respiratori
ill
mari
event
lead
worsen
cardiorespiratori
statu
adult
sever
copd
andor
advanc
chf
associ
rsv
viral
infect
site
nine
countri
bulgaria
canada
czech
republ
franc
germani
itali
russia
sweden
unit
state
northern
hemispher
particip
studi
fall
spring
protocol
approv
independ
institut
review
board
subject
sign
written
inform
consent
enrol
studi
popul
includ
adult
year
age
sever
copd
global
initi
chronic
obstruct
lung
diseas
stage
iiiiv
andor
chf
new
york
heart
associ
class
iiiiv
american
colleg
heart
associ
stage
cd
expect
exposur
children
year
age
least
month
acut
respiratori
ill
ari
defin
new
onset
worsen
least
two
follow
respiratori
symptom
sore
throat
nasal
congest
discharg
hoars
cough
sputum
wheez
dyspnea
pleurit
chest
pain
one
respiratori
symptom
system
symptom
feverish
fatigu
headach
myalgia
worsen
cardiorespiratori
event
defin
follow
aecopd
worsen
major
symptom
dyspnea
sputum
volum
sputum
purul
consecut
day
worsen
one
major
symptom
togeth
anyon
minor
symptom
sore
throat
cold
fever
without
caus
increas
cough
wheez
consecut
day
worsen
chf
defin
chang
symptom
sign
pulmonari
edema
dyspnea
weight
gain
pound
pedal
edema
jugular
venou
distens
tachycardia
tachypnea
beyond
normal
variat
warrant
medic
chang
mari
consid
ill
subject
sought
outpati
inpati
medic
consult
ari
worsen
cardiorespiratori
statu
subject
consid
per
protocol
posit
revers
transcriptas
polymeras
chain
reaction
acut
phase
ill
andor
increas
serum
antibodi
period
surround
health
care
visit
rsv
season
defin
octob
may
follow
year
subject
schedul
studi
visit
everi
may
octob
obtain
blood
nasal
swab
sputum
clinic
data
may
visit
unschedul
ill
visit
collect
blood
nasal
swab
sputum
clinic
data
perform
subject
experienc
mari
visit
ideal
occur
within
hour
longer
day
criteria
confirm
ill
blood
collect
approxim
day
day
ill
onset
schedul
visit
subject
contact
bimonthli
phone
ascertain
mari
occur
outsid
studi
site
urgent
care
emerg
room
er
visit
quantifi
health
care
resourc
util
inform
collect
includ
phone
call
health
care
provid
physician
officeoutpati
visit
er
visit
hospit
intens
care
unit
stay
supplement
oxygen
ventil
use
subject
follow
approxim
year
depend
time
enrol
three
differ
pcr
assay
use
test
rsv
nasal
sputum
sampl
includ
genmark
respiratori
viral
panel
http
wwwgenmarkdxcom
test
common
respiratori
virus
subtyp
pcr
assay
detect
rsv
f
n
serolog
antibodi
measur
enrol
time
mari
acut
approxim
day
ill
convalesc
octob
may
serum
antibodi
measur
use
rsv
neutral
antibodi
assay
rsv
f
ga
gb
igg
electrochemiluminesc
ecl
assay
mesoscal
discoveri
rsv
serorespons
defin
rise
neutral
antibodi
titer
rsv
antigen
ecl
assay
season
baselin
sampl
continu
variabl
summar
descript
statist
includ
mean
standard
deviat
median
rang
confid
interv
unless
otherwis
state
primari
endpoint
object
studi
determin
incid
rate
inpati
outpati
across
multipl
consecut
rsv
season
primari
endpoint
analysi
secondari
outcom
mari
death
perform
adjust
individu
subject
time
four
hundr
subject
enrol
studi
octob
may
patient
subject
meet
studi
criteria
exclud
result
evalu
subject
withdrew
consent
die
lost
withdrew
due
reason
thu
subject
complet
studi
may
figur
mean
age
subject
year
major
sever
copd
advanc
chf
sever
copd
advanc
chf
tabl
cours
studi
episod
mari
ill
occur
hospit
er
visit
outpati
visit
phone
call
health
care
provid
overal
ill
nasal
pcr
perform
within
day
ill
hospit
er
visit
outpati
visit
ill
phone
call
addit
subject
serolog
analysi
postseason
sera
ill
met
definit
posit
increas
serolog
seroposit
rsv
season
combin
incid
event
per
tabl
highest
incid
occur
season
per
follow
season
per
season
per
rate
inpati
highest
season
event
per
follow
season
event
per
incid
outpati
visit
greater
inpati
visit
season
vs
event
per
respect
season
vs
event
per
respect
similar
rsv
season
vs
event
per
respect
twelv
subject
per
protocol
mari
hospit
one
subject
hospit
rsv
outsid
rsv
season
overal
health
util
attribut
rel
low
subject
hospit
increas
oxygen
need
requir
intens
care
subject
die
studi
copd
chf
condit
death
mari
within
week
preced
death
coronaviru
rhinoviru
two
patient
rsv
ill
month
death
one
month
month
death
howev
site
investig
consid
death
unrel
rsv
thirteen
death
summer
outsid
rsv
season
unlik
relat
rsv
infect
thu
overal
mortal
per
death
consid
directli
rsv
relat
invers
relationship
serum
rsv
antibodi
level
incid
observ
figur
higher
antibodi
level
rsv
antigen
associ
lower
incid
relationship
clearli
seen
season
possibl
due
subject
avail
serolog
season
versu
season
vs
respect
season
includ
subject
enrol
throughout
year
preseason
blood
avail
mani
subject
addit
subject
per
protocol
addit
rsv
infect
also
identifi
increas
rsv
antibodi
subject
identifi
rsv
pcr
nonil
visit
februari
enrol
may
schedul
visit
five
subject
evid
two
rsv
infect
differ
season
two
mari
one
season
serorespons
subsequ
season
mari
three
serolog
respons
mari
twenti
subject
serorespons
experienc
mari
outpati
inpati
howev
time
serorespons
could
definit
associ
specif
respiratori
ill
often
acut
titer
risen
baselin
fourfold
rise
titer
acut
convalesc
sampl
demonstr
ill
consid
possibl
includ
per
protocol
incid
rate
determin
consid
definit
plu
possibl
case
outpati
care
sought
hospit
occur
identifi
rsv
infect
consid
identifi
rsv
infect
incid
rsv
infect
per
season
respect
medic
attend
ari
worsen
cardiorespiratori
statu
common
event
per
divers
number
virus
detect
multiplex
pcr
assay
percentag
posit
sampl
season
rsv
influenza
influenza
b
adenoviru
coronavirus
human
metapneumoviru
rhinoviru
parainfluenza
virus
note
coronaviru
rhinoviru
infect
frequent
detect
schedul
nonil
visit
wherea
asymptomat
detect
uncommon
virus
figur
percent
subject
hospit
ari
worsen
cardiorespiratori
statu
hospit
rate
virus
follow
influenza
adenoviru
coronavirus
human
metapneumoviru
rhinoviru
parainfluenza
virus
respect
compar
per
note
rsv
final
assess
ad
valu
test
sputum
sampl
addit
nasal
sampl
use
multiplex
pcr
platform
virus
addit
sputum
test
result
increas
viral
detect
ill
tabl
sever
adult
rsv
diseas
like
multifactori
involv
age
immun
factor
comorbid
presenc
underli
copd
chf
clearli
defin
risk
factor
sever
ill
hospit
prior
howev
popul
adult
class
iiiiv
copd
chf
surpris
ill
sever
expect
previou
studi
adult
copd
chf
vari
stage
includ
mild
moder
diseas
rate
similar
rate
observ
studi
patient
hospit
die
infect
rsv
rsv
infect
includ
serolog
diagnos
studi
consid
subject
hospit
death
notabl
infect
patient
either
asymptomat
mild
ill
requir
medic
intervent
regular
exposur
children
requir
particip
studi
may
led
higher
infect
rate
compar
observ
previou
surveil
vaccin
studi
one
explan
lack
sever
ill
frail
popul
might
regular
exposur
children
result
recent
rsv
infect
studi
lead
increas
protect
baselin
similar
prior
studi
observ
invers
relationship
preinfect
antibodi
level
risk
rsv
infect
suggest
baselin
immun
may
play
role
suscept
infect
howev
abl
compar
baselin
neutral
titer
popul
previou
studi
assay
standard
intern
studi
possibl
health
care
seek
behavior
differ
unit
state
prior
studi
conduct
final
seem
unlik
sever
respiratori
infect
depend
sole
degre
underli
heart
lung
diseas
mechan
contribut
diseas
pathogenesi
popul
yet
defin
sever
issu
regard
diagnosi
rsv
highlight
studi
widespread
use
supplant
form
diagnosi
given
speed
sensit
abil
avoid
convalesc
blood
sampl
valu
evid
howev
serolog
acut
convalesc
sampl
remain
sensit
diagnost
method
shown
previou
studi
confirm
current
rsv
infect
identifi
diagnos
serolog
second
point
test
sputum
provid
significantli
improv
diagnost
yield
virus
compar
nasal
sampl
rang
ad
valu
vari
low
rhinoviru
high
rsv
adenoviru
test
sputum
may
particularli
import
patient
ill
longer
sever
day
present
medic
attent
viru
may
longer
detect
upper
airway
spread
lower
respiratori
tract
notabl
sputum
collect
case
multicent
trial
indic
feasibl
valuabl
patient
copd
respiratori
ill
common
surveil
multipl
virus
document
caus
infect
studi
rhinoviru
frequent
detect
pathogen
although
approxim
occur
routin
nonil
contrast
detect
rsv
virus
uncommon
well
visit
use
multiplex
pcr
diagnosi
percent
sampl
test
posit
rsv
equival
influenza
human
metapneumoviru
hmpv
parainfluenza
virus
coronaviru
detect
rate
rang
although
occasion
detect
well
visit
detect
ill
investig
shown
coronavirus
caus
seriou
ill
person
underli
cardiopulmonari
diseas
yet
remain
underrecogn
pathogen
signific
limit
studi
diagnost
test
perform
ill
trigger
medic
attent
influenza
abrupt
ill
onset
fever
tend
drive
patient
seek
medic
attent
within
sever
typic
rsv
ill
begin
cold
progress
sever
day
dyspnea
wheez
averag
time
seek
medic
attent
day
time
viru
may
longer
detect
upper
addit
rsv
infect
adult
repres
reinfect
rapid
amnest
antibodi
respons
may
obscur
rise
antibodi
acut
sera
collect
delay
final
analysi
acut
convalesc
sera
possibl
patient
die
result
may
bias
toward
milder
ill
summari
rsv
well
respiratori
virus
led
signific
morbid
person
cardiopulmonari
diseas
find
rsv
result
rel
mild
diseas
patient
advanc
copd
chf
highlight
incomplet
understand
diseas
pathogenesi
adult
given
result
immunoprophylaxi
rsv
monoclon
antibodi
select
adult
popul
may
practic
howev
given
overal
burden
rsv
older
adult
program
develop
vaccin
activ
immun
may
feasibl
approach
ar
falsey
mp
griffin
mt
esser
particip
studi
design
collect
analysi
interpret
data
write
report
ee
walsh
particip
collect
analysi
data
review
manuscript
k
shoemak
l
yu
provid
statist
analysi
ar
falsey
mp
griffin
guarantor
paper
take
respons
integr
work
whole
incept
publish
articl
